Diabetes

GLP-1 drugs may fight addiction across every major substance: Study

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction

Novo Nordisk, Abbott tie up to launch second Ozempic brand in India

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

Green vs brown coconut water: Which one is actually healthier for you?

As coconuts mature from green to brown, their sugar levels, electrolyte balance and metabolic impact shift, and doctors explain which version suits your health needs better

Eris Life partners Natco Pharma to launch semaglutide generic in India

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

Thailand halves default sugar in cafes under a nationwide health push

Thailand has redefined 'normal sweetness' in cafe drinks, cutting default sugar by 50% in a nationwide health push aimed at reducing obesity, diabetes and excess sugar intake

Doctors flag risks of relying on HbA1c for diabetes diagnosis in India

Doctors warn that heavy reliance on HbA1c for diabetes diagnosis in India may lead to under- or over-diagnosis due to high anaemia and kidney disease burden, urging multiparametric testing

Why HbA1c, India's most trusted diabetes test, may be getting it wrong

A Lancet Regional Health-Southeast Asia study warns that HbA1c, the gold-standard diabetes test, can misdiagnose or delay diabetes in Indians due to widespread anaemia and blood disorders

Massive global study rewrites what we know about Type 2 diabetes biology

A large global genetics study shows Type 2 diabetes is driven by complex, tissue-specific biology across organs and populations, challenging blood-focused research and treatment strategies

Why more professionals in their 30s and 40s are turning pre-diabetic

Doctors say long sitting hours, stress-filled routines and late meals are fuelling a silent metabolic crisis in urban workplaces

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...

Weight regain after weight loss drugs is common; here's how to prevent it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Is liposomal berberine the new weight-loss fix or just online hype?

Promoted as a natural shortcut to fat loss, liposomal berberine is drawing caution from doctors over safety, drug interactions and misleading comparisons with Ozempic

India faces second highest economic burden due to diabetes: Study

India faces the second highest economic burden due to diabetes of USD 11.4 trillion -- the United States bears the highest costs at USD 16.5 trillion, and China the third at USD 11 trillion, a new study has estimated. Researchers, including those from the International Institute for Applied Systems Analysis and the Vienna University of Economics and Business in Austria, calculated the economic impact of diabetes across 204 countries from 2020 to 2050. Global costs amount to around USD 10 trillion, excluding informal care provided by family members -- about 0.2 per cent of the world's annual gross domestic product (GDP), findings published in the journal Nature Medicine show. Factoring in informal care amounts to up to USD 152 trillion, or 1.7 per cent of the world's yearly GDP, the study estimates. "Caregivers often drop out of the labour market, at least partially, which creates additional economic costs," author Klaus Prettner, professor of macroeconomics and digitalisation at th

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

How type 2 diabetes physically alters the heart and drives failure

A new human heart study shows type 2 diabetes does not just raise cardiac risk but physically alters heart muscle, energy use and structure, helping explain why heart failure is so common in diabetes

Diabetes-related inflammation may harm male fertility, study suggests

Researchers analysing decades of data report that diabetes, especially type 2, is linked to impaired male fertility, driven largely by inflammatory processes in the body

Scientists discover rare new type of diabetes affecting newborns worldwide

Researchers have identified a previously unknown genetic form of neonatal diabetes that begins within weeks of birth and also disrupts brain development, leading to microcephaly and epileptic seizures

Cipla rolls out Afrezza inhaled insulin in India after CDSCO approval

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence

Mounjaro and the brain: Why cravings fade at first, then return later

A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency